about us

ImmunoCellular Therapeutics, Ltd. , based in Los Angeles, is developing immune-based therapies for the treatment of cancer. ImmunoCellular is focused on advancing its Stem-to-T-Cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells. Additional assets, for which the Company is seeking partners, include clinical-stage programs - ICT-107, ICT-121 and ICT-140 - which are patient-specific, dendritic cell-based immunotherapies targeting solid tumors.

About Us Collage

ImmunoCellular's Stem-to-T-Cell program is designed to provide a novel method of harnessing the immune system to manufacture antigen-specific killer T cells that target and destroy cancer cells and provide long-term immuno-surveillance against tumor recurrence. The Stem-to-T-Cell platform has the potential to address many types of cancer, including both solid and hematological tumors.

ICT-107 is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. ImmunoCellular has suspended its phase 3 clinical trial in newly diagnosed glioblastoma.

ICT-121 is a DC immunotherapeutic that targets CD133, an antigen commonly associated with cancer stem cells (CSCs). A 20-patient phase 1 clinical trial in patients with recurrent glioblastoma has been completed.

ICT-140 is a DC immunotherapeutic that targets seven different antigens associated with ovarian cancer, including those expressed by CSCs.

Copyright 2018 by Immunocellular Therapeutics, Ltd.
All Rights Reserved